Tag: Cancer Prevention and Screening

A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

This phase 1 study demonstrated that LY3295668 erbumine, a highly selective, orally bioavailable, and reversible Aurora kinase A inhibitor, both as monotherapy and in combination with standard chemotherapy in children with relapsed/refractory neuroblastoma, had a manageable safety profile. Despite robust preclinical data, relatively modest clinical activity (two partial responses and two minor responses with combination… Continue reading A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

New biomarker test detects early tau tangles in Alzheimer’s disease

Years before tau tangles show up in brain scans of patients with Alzheimer’s disease, a biomarker test developed at the University of Pittsburgh School of Medicine can detect small amounts of the clumping-prone tau protein and its misfolded pathological forms that litter the brain, cerebrospinal fluid and potentially blood, new research published today in Nature… Continue reading New biomarker test detects early tau tangles in Alzheimer’s disease

A new way to detect inflammation

Nearly every disease has an inflammatory component, but blood tests can’t pinpoint inflammation in specific organs or tissues in the human body. Now researchers have developed a method to detect inflammation using antibodies, potentially leading to blood tests for disease-specific biomarkers such as for heart disease, Alzheimer’s disease and various cancers. Their breakthrough also holds… Continue reading A new way to detect inflammation

New screening device shows promise for early lung cancer detection

Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even before symptoms occur. Similar in design to glucose monitoring devices, the sensor provides results from a blood sample in just 40 minutes. The technology has the potential… Continue reading New screening device shows promise for early lung cancer detection

Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG–Positive Neuromyelitis Optica Spectrum Disorder

This longitudinal cohort study determines the optimal timing for assessing serum glial fibrillary acidic protein and serum neurofilament light chain and establishes cutoff values differentiating between attack and remission phases in patients with aquaporin-4 antibody (AQP4-IgG)–positive neuromyelitis optica spectrum disorder across independent cohorts.